Pharmaceuticals company Jeena Sikho Lifecare announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: The company reported revenue of Rs 22,440.48 lakh in Q1FY27, representing a growth of 28.76% YoY from Rs 17,428.59 lakh in Q1FY26 and a growth of 4.11% QoQ from Rs 21,555.32 lakh in Q4FY26. Total Income: For Q1FY27, total income stood at Rs 23,873.13 lakh, up 36.14% YoY compared to Rs 17,535.44 lakh in Q1FY26. On a QoQ basis, total income grew by 9.02% from Rs 21,896.91 lakh in Q4FY26. Profit Before Tax (PBT): The consolidated PBT for Q1FY27 was Rs 8,752.99 lakh, a YoY increase of 27.76% from Rs 6,850.98 lakh in Q1FY26 and a QoQ increase of 42.96% from Rs 6,122.61 lakh in Q4FY26. Net Profit: The company posted a net profit of Rs 6,589.01 lakh for Q1FY27, reflecting a growth of 28.51% YoY from Rs 5,127.14 lakh in Q1FY26 and a 46.17% increase QoQ from Rs 4,507.77 lakh in Q4FY26. Total Comprehensive Income: For the quarter ended Q1FY27, total comprehensive income was Rs 6,636.23 lakh, compared to Rs 5,171.31 lakh in Q1FY26 (YoY growth of 28.33%) and Rs 4,513.28 lakh in Q4FY26 (QoQ growth of 47.04%). Earnings Per Share (EPS): Basic EPS improved to Rs 5.30 in Q1FY27 from Rs 4.12 in Q1FY26 and Rs 3.63 in Q4FY26. Standalone Financial Highlights: Revenue from Operations: Standalone revenue for Q1FY27 was Rs 22,440.48 lakh, registering a YoY growth of 28.76% from Rs 17,428.59 lakh in Q1FY26 and a QoQ growth of 4.11% from Rs 21,555.07 lakh in Q4FY26. Total Income: Standalone total income stood at Rs 23,841.99 lakh in Q1FY27, up 35.97% YoY from Rs 17,535.44 lakh in Q1FY26 and up 8.80% QoQ from Rs 21,912.94 lakh in Q4FY26. Net Profit: Standalone net profit for Q1FY27 was Rs 6,569.18 lakh, an increase of 28.03% YoY from Rs 5,131.14 lakh in Q1FY26 and 44.85% QoQ from Rs 4,535.18 lakh in Q4FY26. Business Highlights: Segment Performance (Consolidated): Ayurvedic Products/Medicines: This segment contributed Rs 11,828.31 lakh to revenue in Q1FY27, compared to Rs 8,002.51 lakh in Q1FY26 (YoY growth of 47.81%). Ayurvedic Healthcare Services: This segment recorded revenue of Rs 10,474.66 lakh in Q1FY27, compared to Rs 9,426.08 lakh in Q1FY26 (YoY growth of 11.12%). Others: This segment (comprising royalty income and diagnostic services) contributed Rs 137.51 lakh in Q1FY27. Asset Monetization: The Board approved the sale of the land and building of its Derabassi hospital facility to M/s VSB Enterprises for Rs 9.05 crore. The company intends to continue operating the hospital from the same premises under a lease arrangement. International Expansion: The company's subsidiary, Jeena Sikho International LLC, is in the process of acquiring a 51% equity stake in Back to Roots Ayurveda by Dr. Shyam LLC, UAE. A profit share of Rs 0.53 crore from this venture was booked in the consolidated results for Q1FY27. Dividends: During the current quarter, the Board recommended a final dividend of Rs 4.50 per equity share for the year ended March 31, 2026 (FY26), subject to shareholder approval. Board Re-appointments: The Board approved the re-appointment of Mr. Manish Grover as Managing Director, Mrs. Bhavna Grover as Whole-time Director, and Mr. Karan Vir Bindra as Independent Director for second terms of five years each, starting from August 25, 2026. Result PDF
Pharmaceuticals company Jeena Sikho Lifecare announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: Stood at Rs 21,555.32 lakh in Q4FY26, witnessing a strong YoY growth of 54.80% compared to Rs 13,925.06 lakh in Q4FY25, but recording a QoQ decrease of 2.76% from Rs 22,167.97 lakh in Q3FY26. For FY26, revenue increased by 70.84% YoY to Rs 80,136.39 lakh against Rs 46,907.19 lakh in FY25. Total Income: Reached Rs 21,896.91 lakh in Q4FY26, registering an increase of 56.95% YoY from Rs 13,951.97 lakh in Q4FY25, and a decline of 2.35% QoQ from Rs 22,424.65 lakh in Q3FY26. For FY26, total income stood at Rs 80,986.00 lakh, up by 70.21% YoY from Rs 47,580.73 lakh in FY25. Net Profit: Reported at Rs 4,507.77 lakh in Q4FY26, displaying a robust YoY growth of 77.89% from Rs 2,533.97 lakh in Q4FY25, while falling by 32.31% QoQ compared to Rs 6,659.89 lakh in Q3FY26. On an annual basis, the net profit for FY26 surged impressively by 177.32% YoY to Rs 22,169.81 lakh from Rs 7,994.33 lakh in FY25. Standalone Financial Highlights: Revenue from Operations: Recorded at Rs 21,555.07 lakh in Q4FY26, up by 54.80% YoY from Rs 13,925.06 lakh in Q4FY25, and down by 2.76% QoQ from Rs 22,166.47 lakh in Q3FY26. For FY26, revenue stood at Rs 80,134.64 lakh, growing 70.84% YoY from Rs 46,907.19 lakh in FY25. Total Income: Stood at Rs 21,912.94 lakh in Q4FY26, an increase of 57.06% YoY against Rs 13,951.97 lakh in Q4FY25, and a drop of 2.28% QoQ from Rs 22,423.15 lakh in Q3FY26. For FY26, total income grew by 70.24% YoY to Rs 81,000.53 lakh compared to Rs 47,580.73 lakh in FY25. Net Profit: Stood at Rs 4,535.18 lakh in Q4FY26, reflecting a YoY growth of 78.98% from Rs 2,533.97 lakh in Q4FY25, and a QoQ decline of 32.03% from Rs 6,672.67 lakh in Q3FY26. For FY26, net profit skyrocketed by 177.92% YoY to Rs 22,217.57 lakh from Rs 7,994.33 lakh in FY25. Business Highlights & Segment-wise Performance: Ayurvedic Products/Medicines Segment: Generated a revenue of Rs 11,797.98 lakh in Q4FY26, marking a YoY growth of 71.92% from Rs 6,862.39 lakh in Q4FY25, but slightly down by 3.11% QoQ from Rs 12,176.52 lakh in Q3FY26. For FY26, the segment’s revenue stood at Rs 41,569.28 lakh, growing by 93.03% YoY from Rs 21,535.59 lakh in FY25 (Consolidated figures). Ayurvedic Healthcare Services Segment: Recorded Q4FY26 revenue of Rs 9,532.10 lakh, an increase of 34.96% YoY compared to Rs 7,062.67 lakh in Q4FY25, and a decrease of 4.58% QoQ from Rs 9,989.95 lakh in Q3FY26. Annual revenue for FY26 stood at Rs 38,340.37 lakh, up 51.11% YoY from Rs 25,371.60 lakh in FY25 (Consolidated figures). Others Segment: Contributed a revenue of Rs 225.24 lakh in Q4FY26 and Rs 226.74 lakh For FY26. Dividend: The Board of Directors has recommended a final dividend of Rs 4.50/- per equity share (having a face value of Rs 2/- each) for the financial year 2025-26. Global Expansion & Acquisitions: The Company's wholly-owned UAE subsidiary, Jeena Sikho International LLC (JSIL), entered into a Share Purchase Agreement on 07 January 2026 to acquire a 51% equity stake in Back to Roots Ayurveda by Dr. Shyam LLC, UAE. Strategic Investment: The Company acquired 18 lakh share warrants of Chandan Healthcare Limited at an issue price of Rs 234 per warrant. Out of the total aggregate consideration of Rs 4,212 lakh, the Company paid 25% (Rs 1,053 lakh) upfront on 02 February 2026. ESOP Grant: On 01 January 2026, the Nomination and Remuneration Committee approved the grant of 2,18,875 Employee stock options to 1,176 eligible employees. Result PDF
Pharmaceuticals company Jeena Sikho Lifecare announced Q3FY26 results Revenue: Rs 22,166 crore against Rs 11,569 crore during Q3FY25, change 92%. EBITDA: Rs 10,080 crore against Rs 2,961 crore during Q3FY25, change 240%. EBITDA Margin: 45% for Q3FY26. PBT: Rs 8,906 crore against Rs 1,774 crore during Q3FY25, change 402%. PAT: Rs 6,673 crore against Rs 1,321 crore during Q3FY25, change 405%. EPS: Rs 5.37 for Q3FY26. Acharya Manish Ji, Managing director, said: Jeena Sikho has delivered yet another robust quarter, continuing its strong momentum from the first half of FY26. The Company’s performance in Q3 further strengthens its track record of consistent growth and operational excellence, with solid contributions from both business verticals, Ayurveda Healthcare Services and Ayurveda Healthcare Products. Revenue from Operations grew by an impressive 92% YOY in Q3 and 78% YOY for 9MFY26. This growth was primarily driven by sustained volume expansion across business segments and the continued strengthening of our pan-India presence. Profitability remained on a strong footing, with EBITDA margins steady at 45% in Q3, reflecting operational efficiency despite ongoing investments in business expansion. On a year-to-date basis, 9MFY26 EBITDA margins improved significantly to 46%, compared to 29% in FY25, underscoring the growing scalability and efficiency of our business model. In our services segment, patient volumes remained robust across both IPD and OPD formats, resulting in higher throughput and overall service revenue. Our Day Care centres and Video-Call consultations have shown tremendous traction, further augmenting our reach and accessibility. The Company continues to benefit from increasing nationwide awareness and acceptance of Ayurvedic healthcare solutions. Looking ahead, the services business is well-positioned to deliver sustained growth, supported by a strong bed pipeline. We currently have 475+ beds under development, providing good visibility for capacity additions across existing and new facilities, which will drive further volume-led growth in the coming quarters. On the innovation front, we are gearing up to launch the Jeena Sikho Health Card, an initiative designed to offer enhanced value and convenience to our customers. More details on this will be shared in the upcoming quarters. Our Ayurveda healthcare products segment also continues to gain momentum, supported by successful recent product launches and growing demand for our legacy portfolio. The category’s strong performance validates our strategy of product diversification and consistent focus on quality and innovation. In conclusion, Jeena Sikho remains firmly positioned to sustain its strong growth trajectory. With strategic initiatives in capacity expansion, market diversification (including international expansion), operational excellence, and a differentiated product portfolio, the Company is well-prepared to deliver consistent growth and long-term value for all stakeholders. Result PDF